Skip to main content
Download PDF

Fanca deficiency is associated with alterations in osteoclastogenesis that are rescued by TNFα

Cell & Bioscience volume 13, Article number: 115 (2023) Cite this article

Abstract

Background

Hematopoietic stem cells (HSCs) reside in the bone marrow (BM) niche, which includes bone-forming and bone-resorbing cells, i.e., osteoblasts (OBs) and osteoclasts (OCs). OBs originate from mesenchymal progenitors, while OCs are derived from HSCs. Self-renewal, proliferation and differentiation of HSCs are under the control of regulatory signals generated by OBs and OCs within the BM niche. Consequently, OBs and OCs control both bone physiology and hematopoiesis. Since the human developmental and bone marrow failure genetic syndrome fanconi anemia (FA) presents with skeletal abnormalities, osteoporosis and HSC impairment, we wanted to test the hypothesis that the main pathological abnormalities of FA could be related to a defect in OC physiology and/or in bone homeostasis.

Results

We revealed here that the intrinsic differentiation of OCs from a Fanca−/− mouse is impaired in vitro due to overactivation of the p53–p21 axis and defects in NF-kB signaling. The OC differentiation abnormalities observed in vitro were rescued by treating Fanca−/− cells with the p53 inhibitor pifithrin-α, by treatment with the proinflammatory cytokine TNFα or by coculturing them with Fanca-proficient or Fanca-deficient osteoblastic cells.

Conclusions

Overall, our results highlight an unappreciated role of Fanca in OC differentiation that is potentially circumvented in vivo by the presence of OBs and TNFα in the BM niche.

Background

Bone marrow failure (BMF), myelodysplasia (MDS) and acute myeloid leukemia (AML) are three pathological conditions with underlying alterations in hematopoietic stem and progenitor cells (HSPCs) due to the cytotoxic consequences of exogenous stress (DNA damage) as well as to acquired or inherited mutations in genes encoding proteins involved in several classes of biological functions, including epigenetics [1, 2], RNA transcription and/or splicing [3,4,5], metabolism [6, 7], signaling [8, 9], DNA repair [10,11,12], ribosome biogenesis [13, 14] and/or telomere maintenance [15, 16].

After birth, HSPCs are localized in a specific microenvironment in the bone marrow (BM), the hematopoietic niche. Niche homeostasis is determined by tightly regulated crosstalk between HSPCs and niche components that regulates the quiescence, proliferation, and differentiation of the former and influences the dynamics of the latter [17, 18]. Indeed, although BMF, MDS and AML have long been considered HSPC-autonomous disorders whose development is driven by cell-intrinsic events, several observations definitively support a key role of the HSPC microenvironment in the initiation, selection, and progression of these three conditions [19,20,21]. Bone-forming osteoblasts (OBs) originating from mesenchymal stem cells (MSCs) and bone-resorbing osteoclasts (OCs) originating from HSPCs are key components of the niche and are known to have a major influence on both healthy and pathological HSPC behavior [22,23,24,25]. Accordingly, analyses of experimental mouse models or human pathologies have shown that specific gene mutations [26, 27] and functional deficiencies in OBs and/or OCs [28,29,30] are, per se, sufficient to generate BMF, MDS and AML.

Fanconi anemia (FA) is a DNA repair deficiency syndrome linked to BMF and cancer predisposition (especially MDS and AML) [31]. To date, more than 20 genes are known to be mutated in FA, with FANCA accounting for more than 60% of all FA cases [32]. FA-related proteins participate in a pathway involved in DNA interstrand crosslink (ICL) repair and in the rescue of stalled replication forks, ensuring maintenance of genetic and chromosomal integrity [33, 34]. However, in addition to their key roles in DNA repair and replication rescue, at least some of the FA-related proteins have other functions, the alteration of which contributes in an as yet poorly determined way to the symptoms of this syndrome. BMF, MDS and AML in FA are associated with DNA damage accumulation and genetic instability but also with alterations in senescence [35, 36]; nucleolar homeostasis and ribosome biogenesis [37,38,39] as well as in the activity of several stress signaling pathways, such as p38MAPK, PI3K/AKT and NF-kB [40,41,42]; increased expression or sensitivity to several proinflammatory cytokines, such as TNFα and TGFβ [41, 43, 44]; and the unrestrained expression or activity of p53 [45, 46], Myc [47] and/or microphthalmia transcription factor (MiTF) [48].

In addition to hematopoietic defects, FA patients have a high incidence of mesenchymal tissue-derived congenital malformations and osteoporosis [49,50,51,52], suggesting a role of FA-related proteins in osteogenesis and bone maintenance. Despite these clinical observations suggesting multiple mesenchymal defects, relatively little attention has been directed to the association between abnormal HSC functions and the BM microenvironment in FA [49]. Therefore, we wanted to determine whether the process of OC differentiation from precursors (or osteoclastogenesis) was altered in FA.

Results

Fanca deficiency is associated with altered osteoclastogenesis

To explore the role of Fanca in osteoclastogenesis, we isolated BM cells from 3- to 4-month-old WT and Fanca−/− mice and treated them with macrophage colony stimulating factor (M-CSF) (25 ng/ml) for 48 h to induce OC precursor proliferation. The resulting cells were harvested, counted, resuspended in complete medium supplemented with M-CSF (50 ng/ml) and RANKL (50 ng/ml) and seeded at 75,000 cells/cm2 to terminally differentiate into multinucleated OCs (i.e., cells containing at least 3 nuclei) that appeared by day 3 (Fig. 1A). OC formation was monitored by tartrate-resistant acid phosphatase (TRAP) staining (Fig. 1B) or by immunofluorescence (IF) targeting the actin-F cytoskeleton (Fig. 1C). Compared with their WT counterparts, Fanca−/− cells generated fewer syncytia, each containing fewer nuclei and occupying a smaller area (Fig. 1D, left to right). Comparable results were observed in 1-year-old mice (Additional file 1: Fig. S1A). Next, we demonstrated in WT cells that Fanca expression is maintained without major changes at both the mRNA and protein levels during the differentiation process from precursors to OCs (Additional file 1: Fig. S1B and C). In the knockout (KO) mice, Fanca was undetectable by qPCR and Western blot analysis, confirming gene inactivation and the absence of the protein.

Fig. 1
figure 1

Fanca deficiency is associated with altered osteoclastogenesis. A Representation of the strategy used to differentiate OCs from isolated BM cell populations. B TRAP staining of OCs from WT and Fanca−/− mice at day 5 of differentiation. C Representative images of F-actin IF in OCs from WT and Fanca−/− mice at day 5 of differentiation. D Number of OCs per field (left), number of nuclei for OC (middle) and surface of the OCs (right) at days 3, 4 and 5 of differentiation. E Representative images after TRAP staining of OCs from WT and Fanca−/− mice at day 4 of differentiation after treatment with the indicated doses of RANKL. F Number of OCs per field (left), number of nuclei for OC (middle) and surface of the OCs (right) at day 4 of differentiation after treatment with the indicated doses of RANKL. Data are shown as the mean ± SEM. Each small circle represents an individual mouse. Statistical analysis was performed by t tests: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Full size image

Finally, we analyzed the behavior of the precursors treated with increasing doses of RANKL (25, 50 or 100 ng/ml). At higher doses of RANKL, the cells that merged in a syncytium (Fig. 1F, middle) and the surface of the latter (Fig. 1F, right) increased in both WT and Fanca−/− cells, whereas the number of OCs per field increased significantly only in Fanca−/− cells (Fig. 1F, left). Notably, even if osteoclastogenesis in Fanca−/−-derived cells remained significantly lower than that in their WT counterparts when compared at the same dose of RANKL, it appeared that OC differentiation at 100 ng/ml cytokine in Fanca−/− cells was comparable to that observed at 25 ng/ml in WT cells.

Thus, our in vitro observations robustly demonstrated that Fanca deficiency affects OC differentiation, impacting their fusion and maturation processes.

Fanca −/−-associated osteoclastogenic abnormalities rely on reduced Nfact1 expression

To identify altered partners and/or pathways involved in the Fanca−/−-associated osteoclastogenesis defect, we analyzed the expression of known key elements involved in OC differentiation by qPCR and/or Western blotting. We first demonstrated that the receptors of M-CSF and RANKL, M-Csfr and Rank, respectively, were similarly expressed at the mRNA level in both WT and Fanca−/− cells (Fig. 2A). Subsequently, we determined the induction of Nfatc1, the key osteogenic transcription factor that activates downstream RANKL exposure and drives OC differentiation [53]. Compared to WT cells, Fanca−/− OCs exhibited significantly lower Nfatc1 expression at both the mRNA and protein levels (Fig. 2B and D). In accordance with its reduced expression, the mRNA expression of the key Nfatc1 targets [53] Oscar (a marker of OC differentiation), Dc-Stamp and Atp6v0d2 (membrane proteins involved in OC precursor fusion) and Cathepsin K and Trap (involved in bone resorption) was also significantly decreased in Fanca−/− OCs (Fig. 2C). The decrease in Cathepsin K was also validated at the protein level (Fig. 2D). The same key osteoclastogenic effectors also showed downregulated expression in 1-year-old Fanca−/− mice (Additional file 1: Fig. S2A and B).

Fig. 2
figure 2

Fanca deficiency leads to impaired osteoclastogenesis at the molecular level. A Relative Rank and M-Csfr expression evaluated by qRT-PCR in progenitors and OCs from WT and Fanca−/− mice at day 4 of differentiation. B Relative Nfatc1 expression evaluated by qRT-PCR in progenitors and OCs from WT and Fanca−/− mice at day 4 of differentiation. C Relative Oscar, Dc-Stamp, Atp6v0d2, cathepsin K and TRAP expression evaluated by qRT-PCR in progenitors and OCs from WT and Fanca−/− mice at day 4 of differentiation. D Representative Western blot showing Nfatc1 and Cathepsin K in OCs from WT and Fanca−/− mice at days 4 and 5 of differentiation. Relative protein expression of Nfatc1 and Cathepsin K in WT and Fanca−/− mice at days 4 and 5 of differentiation. β-Actin was used as a loading control. Data are shown as the mean ± SEM. Each small circle represents an individual mouse. Statistical analysis was performed by t tests: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Full size image

The expression of Mitf, another key osteoclastogenic transcription factor connected to the FANC pathway [54, 55] that we previously described as dysregulated in FA cells [48], was similar between the WT and Fanca−/− OCs (Additional file 1: Fig. S2C), suggesting that its deregulation in FA is cell type dependent.

Altogether, our analysis indicates that the observed defect in osteoclastogenesis in the absence of Fanca relies on early events linked to the expression/activity of Nfatc1.

p53 participates in the impaired osteoclastogenesis induced by Fanca KO

Previous observations reported an unscheduled constitutive activation of the p53 signaling pathway in cells from FA patients and mice [35, 45, 46] that impacts hematopoietic stem and precursor cell behavior [45]. Since p53 “constitutive” activation in response to its well-known activator Nutlin-3 impairs osteoclastogenesis [56] and activated p53 can potentially lead to downregulated Nfatc1 expression [57], we wanted to monitor OC differentiation from Fanca−/− cells in the presence of either Nulin-3 or the p53 inhibitor pifithrin-α. First, to validate the impact of each drug on the activity of p53, we quantified the mRNA expression of the key p53 target Cdkn1a encoding the cyclin-dependent kinase inhibitor p21 by qPCR. In accordance with the known increased basal level of p53 activity downstream of the loss-of-function of Fanca, Cdk1a levels were more elevated in untreated Fanca−/− than in WT progenitors (Fig. 3A). Next, having validated that in both WT and Fanca−/− cells, Nutlin-3 exposure increased Cdkn1a expression, whereas treatment with pifithrin-α decreased it, we determined OC differentiation in cells exposed to one or the other drug. In WT cells, even if the number of formed OCs remained the same, both p53 activation and inhibition restrained the number of cells that merged in a syncytium and, consequently, their surface (Fig. 3B), suggesting that, at least in vitro, well-regulated p53 activity is necessary for proper osteoclastogenesis. Supporting an inhibitory role of p53 activity in the delayed process of osteoclastogenesis in Fanca−/− cells, its inhibition by pifithrin-α rescued the number of formed OCs, the number of cells that merged in a syncytium and their surface (Fig. 3B) at a level that is statistically indistinguishable from that of the WT cells under standard conditions. Exposure of Fanca−/− cells to Nutlin-3 did not modify their behavior. However, despite the improvement in osteoclastogenesis, the expression of the mRNAs encoding Nfatc1, Dc-Stamp and Cathepsin-K was not modified in pifithrin-α-treated Fanca−/− cells (Fig. 3C).

Fig. 3
figure 3

p53–p21 participates in impaired osteoclastogenesis induced by Fanca KO. A Relative Cdkn1a expression evaluated by qRT-PCR in progenitors, OCs and OCs from WT and Fanca−/− mice treated with Nutlin-3 or pifithrin-α (Nut and Pif, 1 μM each) at days 4 and 5 of differentiation. B Number of OCs for field (left), number of nuclei for OC (middle) and surface of the OCs (right) from the WT and Fanca−/− mice at day 5 of differentiation after Nutlin-3 (Nut) or Pifithrin-α (Pif) treatment (1 μM each). C–E Relative Nfatc1, DC-Stamp and cathepsin K expression evaluated by qRT-PCR in progenitors, OCs and OCs from Fanca−/− mice treated with Nutlin-3 or pifithrin-α (Nut and Pif, 1 μM each) at days 4 and 5 of differentiation. Data are shown as the mean ± SEM. Each small circle represents an individual mouse. Statistical analysis was performed by t tests: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Full size image

Thus, although our data support a key role for the unscheduled increase in p53 signaling in the impaired osteoclastogenesis observed in Fanca−/− cells, it appears that such an effect is likely due to the known effects of p53 on several aspects of cellular behavior, such as the cell cycle, apoptosis and/or senescence, rather than a direct impact on the control of specific pathways involved in OC differentiation.

TNFα treatment rescues osteoclastogenesis in Fanca −/− cells by increasing NF-kB activity

TGFβ and TNFα are two extracellular molecules known to regulate osteoclastogenesis [58, 59], and their signaling pathways have been identified as constitutively active, even in the absence of detected cytokine expression, FA [41, 44]. We did not detect either of the two proteins in the culture medium of differentiated OCs from our Fanca−/− mice as already described in vivo or in cell culture from FANC-KO mouse models (data not shown). Whereas TGFβ exposure had limited consequences on OC differentiation in both WT and Fanca−/− cells and no effect on the number of scored OCs per field (Additional file 1: Fig. S3), TNFα exposure fully rescued osteoclastogenesis in Fanca−/− cells without modifying the dynamics of the differentiation process of the WT cells (Fig. 4A). Indeed, TNFα exposure normalized not only the number of OCs per field, the number of nuclei for OC and the area of each syncytium (Fig. 4A) but also the expression of the OC differentiation-associated mRNAs Nfatc1, Dc-Stamp and Cathepsin K (Fig. 4B). Normalization was also validated at the protein level for Nfatc1 and cathepsin K (Fig. 4C). Moreover, we also observed that the expression of Cdkn1a was significantly downregulated in Fanca−/− cells differentiated in the presence of TNFα (Fig. 4D), as previously observed following pifithrin-α treatment, suggesting that TNFα exposure opposes the consequences of unscheduled p53–p21 axis activity that negatively influences the behavior of Fanca−/− OCs.

Fig. 4
figure 4

TNFα treatment rescues impaired osteoclastogenesis induced by Fanca KO. A Number of OCs for field (left), number of nuclei for OC (middle) and surface of the OCs (right) from the WT and Fanca−/− mice at day 4 of differentiation after TNFα treatment (10 ng/ml). B Relative Nfatc1, Dc-Stamp and Cathepsin K expression evaluated by qRT-PCR in progenitors, OCs and OCs treated with TNFα at day 4 of differentiation from the WT and Fanca−/− mice. C Left: Western blot showing Nfatc1 and Cathepsin K in OCs from WT and Fanca−/− mice at day 4 of differentiation that were left untreated or treated with TNFα. β-Actin was used as a loading control. Right: Relative protein expression of Nfatc1 and Cathepsin K in OCs from WT and Fanca−/− mice at day 4 of differentiation that were left untreated or treated with TNFα. D Relative Cdkn1a expression evaluated by qRT-PCR in progenitors, OCs and OCs treated with TNFα at day 4 of differentiation from WT and Fanca−/− mice. Data are shown as the mean ± SEM. Each small circle represents an individual mouse. Statistical analysis was performed by t tests: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Full size image

TNFα exposure stimulates NF-kB signaling, which participates in osteoclastogenesis fostering Nfatc1 activity [60]. To indirectly evaluate NF-kB activity in Fanca−/− OCs in response to TNFα we determined the level of phosphorylation of RelA/p65 and the expression of RelB, both of which are able to interact with p50, cleaved from the p105 precursor, forming dimers that constitute the transcriptionally active forms of the canonical NF-kB pathway that are specifically induced by the cytokine. At 4 days of differentiation, the levels of P-p65 and RelB were significantly more elevated in Fanca−/− OCs treated with TNFα than in their absence, supporting the hypothesis that the improved osteoclastogenesis observed in the presence of the cytokine in Fanca−/− OCs is due to increased NF-kB activity (Fig. 5A and B).

Fig. 5
figure 5

NF-kB status in OCs from WT and Fanca−/− mice with or without TNFα. A Representative Western blot showing NF-kB canonical and noncanonical signaling pathway protein levels 4 days postdifferentiation in OCs from WT and Fanca−/− mice with or without TNFα. β-Actin was used as a loading control. B Quantification of data concerning P-p65, p105, p50 and RelB 4 days postdifferentiation in OCs from WT and Fanca−/− mice left untreated (NT) or treated with TNFα. Blue bars are for WT and red bars for Fanca-/- OCs. Data are shown as the mean ± SEM. Each small circle represents an individual mouse. Statistical analysis was performed by t tests: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Full size image

Thus, our observations indicate that in vitro osteoclastogenesis is impaired in Fanca−/− cells as a consequence of impairment in both the p53 and NF-kB signaling pathways associated with Fanca loss-of-function, which can be rescued by TNFα exposure.

Coculture of Fanca −/− OCs with OB-like cells, mimicking in vivo conditions, rescues osteoclastogenesis

Our previous in vitro data unveiling a defect in OC differentiation are in contrast with previously published observations showing, in FA patients and mouse models, an osteoporotic phenotype possibly associated with a defect in OB activity (Ref). Our Fanca−/− mice developed normally, with no signs of skeletal abnormalities. However, a quantitative computed tomography analysis of the femur (Fig. 6A and Additional file 1: Fig. S4A) revealed that although the trabecular bone density was similar between the WT and Fanca−/− mice (Additional file 1: Fig. S4B), the cortical bone in the Fanca−/− mice was thinner, and its area was reduced (Fig. 6B). Thus, even in the absence of frank osteoporosis, the tomographic analysis is consistent with data from the literature that support a deficit in bone formation/accumulation and in contrast with the expectations of our in vitro data.

Fig. 6
figure 6

µCT analysis of femurs from Wt and Fanca−/− mice. A Representative µCT images of the distal femur and femur section in WT and Fanca−/− mice. B Comparison of femur cross-section geometry between WT and Fanca−/− mice

Full size image

To shed light on the previous apparent parodox and given that TNFα exposure rescues Fanca−/− osteoclastogenesis in vitro and that OC differentiation occurs on the bone endosteal surface under the control of OBs, which produce RANKL and TNFα, we decided to mimic this physiological setting in vitro. We layered WT or Fanca−/− OC precursors on WT or siRNA Fanca-depleted MC3T3 murine cells, a widely accepted in vitro model of OBs [61]. The WT OC precursors cultured on the WT or siFanca-silenced MC3T3 cells differentiated into OCs (Fig. 7A). Compared to what we previously observed in cells cultured alone, the difference between Fanca−/− and WT precursors was drastically reduced but still significant when Fanca−/− cells were cultured on WT MC3T3 cells (Fig. 7A). Interestingly, when Fanca−/− OC precursors were cocultured with Fanca-depleted OB-like MC3T3 cells, osteoclastogenesis was fully rescued (Fig. 7A). Importantly, as observed following TNFα exposure (Fig. 4), coculture conditions canceled the difference in the expression of Nfatc1, Cathepsin K and Cdkn1a between the WT and Fanca−/− OCs at the mRNA and/or protein level (Fig. 7B and C). While an enzyme-linked immunosorbent assay (ELISA) of the culture medium did not reveal the presence of secreted TNFα (not shown), FACS analysis (Fig. 7D) demonstrated its presence at the cell membrane on both the WT and siFANCA-depleted MC3T3 cells. Notably, membrane-associated TNFα levels were slightly but systematically higher in Fanca-depleted MC3T3 cells than in Fanca-proficient MC3T3 cells. Next, to validate the role of TNFα in rescuing the defect in osteoclastogenesis in Fanca−/− cells, we added a neutralizing TNFα antibody to WT or Fanca-depleted MC3T3 cells before adding WT or Fanca−/− OC progenitors. OC progenitors from the same WT or Fanca−/− mouse were cultured ‘alone’ in the absence or presence of TNFα, or seeded on WT or Fanca-depleted MC3T3 cells in the presence or absence of a neutralizing TNFα antibody. Exposure to TNFα (Additional file 1: Fig. S5A) or coculture with the WT or Fanca-depleted MC3T3 cells (Additional file 1: Fig. S5B) fostered and normalized Fanca−/− osteoclastogenesis. Supporting the role of membrane-associated TNFα in rescuing Fanca−/− osteoclastogenesis, the coculture of Fanca−/− cells on Fanca-proficient or Fanca-deficient MC3T3 cells in the presence of neutralizing anti-TNFα significantly reduced their differentiation (Fig. 7E). Under similar culture conditions, the behavior of WT OCs remained the same (Additional file 1: Fig. S5C).

Fig. 7
figure 7

Coculture with the preosteoblastic cell line MC3T3 rescues impaired osteoclastogenesis induced by Fanca KO. A Number of OCs per field from WT and Fanca−/− cells plated on WT or Fanca-depleted MC3T3 cells at day 4 of differentiation. B Relative Nfatc1, Cathepsin K and Cdkn1a expression evaluated by qRT-PCR in OCs from WT and Fanca−/− mice cocultured with WT or Fanca-depleted MC3T3 cells at day 4 of differentiation. C Western blot showing Fanca, Nfatc1 and Cathepsin K in OCs from WT and Fanca−/− mice at day 4 of differentiation plated on WT or Fanca-depleted MC3T3 cells. β-Actin was used as a loading control. Middle and right: Relative protein expression of Nfatc1 and Cathepsin K in OCs from WT and Fanca−/− mice at day 4 of differentiation plated on WT or Fanca-depleted MC3T3 cells. D Relative TNFα level in the WT or siFanca-depleted MC3T3 cells as evaluated by FACS analysis. E Number of OCs per field from Fanca−/− cells plated on WT or Fanca-depleted MC3T3 cells and left untreated (NT) or treated with an anti-TNFα neutralizing antibody (10 ng/ml) at day 4 of differentiation. Data are shown as the mean ± SEM. Each small circle represents an individual analyzed mouse or individual experiment (D). Statistical analysis was performed by t tests: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Full size image

Thus, our analysis revealed that the observed defect in OC differentiation in Fanca−/− cells can be rescued by TNFα and strongly supports the hypothesis that osteoclastogenesis in Fanca-deficient cells requires cytokines.

Thus, according to previously published observations, bone formation in FA appears impaired even if in vivo OC differentiation, which is clearly deficient per se, is rescued due to the cytokines present on the cells of the BM niche.

Discussion

In this study, we demonstrated that the loss of Fanca function is associated with a defect in OC differentiation. Our data link the impairment of osteoclastogenesis to FA-associated dysregulation of p53–p21 and the NF-kB axis, both fully rescued in vitro by exposure to TNFα or by coculture with OB-like cells, which expose TNFα at their cytosolic membrane. Therefore, in vivo, the differentiation defect remains cryptic and hidden by the presence of OBs in the endosteum and/or TNFα in the local microenvironment. Bone histological analysis showed that the Fanca−/− mice presented bone abnormalities in their cortical bone component compatible with osteoporotic pathology, as previously described.

Historically, all efforts made to elucidate the pathogenesis of FA have focused on the hematopoietic system at the HSC level, with relatively little attention given to the intrinsic differentiation process of the different lineages. Indeed, it has been proposed that BMF in FA relies on HSC attrition resulting from a combination of alterations in cell proliferation associated with unscheduled p53 [45, 47], MiTF [48] and/or MYC [47] expression and increased accumulation of DNA damage and genetic instability that arises when HSCs exit quiescence [62, 63], which pushes cells through differentiation, limiting self-renewal of potentially mutated HSCs [64, 65]. FA cells show altered expression, signaling and/or responses to several growth factors and proinflammatory cytokines, including TGFβ [44] and TNFα [43], whose origins and consequences are still poorly understood.

Moreover, evidence suggests that FANC pathway loss of function affects bone homeostasis and the skeletal system: FA patients display congenital abnormalities of the skeleton, mesenchymal tissue-derived malformations, and osteoporosis [49] partially recapitulated in embryos and/or adult Fancc−/−, Fancg−/−, Fancd2−/− and Fancc−/−–Fancg−/− double-KO (DKO) mice. Defects were related to altered osteogenic differentiation potential of bone marrow‐derived mesenchymal stem cells (BM-MSCs) but not defects in OC differentiation [49, 66,67,68].

Our analysis indicates that in our mouse model [69], the loss of Fanca−/− affects hematopoiesis not only ‘quantitatively’, reducing the HSC pool but also functionally, altering the differentiation of OCs, which are a specific hematopoietic lineage. A ‘differentiation’ specific activity of Fanca has been reported for the process of megakaryopoiesis in Fanca−/− mice [70] and for erythroid differentiation in human FANCA-deficient cells [62].

Our data validate and extend our knowledge of the negative consequences of the unscheduled activation of the p53–p21 axis in FA, which participates in HSC dysfunction [45] and defects in erythropoiesis [62]. However, p53 inhibition is not sufficient to completely correct deficient osteoclastogenesis in Fanca−/− cells, as observed in response to TNFα. Exposure to the cytokine rescues the expression of p21 (as does p53 inhibition) as well as the expression of all targets of Nfatc1, the key driver of osteoclastogenesis. Thus, we propose that TNFα, by normalizing NF-kB signaling, promotes increased Nfatc1 activity on its canonical targets and ‘re-equilibrates’ p21 expression, allowing Fanca−/− OC differentiation to proceed.

Conclusions

We speculate that the overexpression of TNFα might represent a kind of adaptive response of the organism to ensure optimal OC differentiation despite the possible negative consequences of this cytokine on the behavior of other cell lines in FA, including on OB-mediated bone formation. A better understanding of the niche physiology in FA may help to establish supportive care for patients, delaying BMF, MDS and AML and supporting transplantation.

Limitations of the study

Our study was conducted exclusively in mice and on one out of 23 FANC genes. Further studies are needed to evaluate whether depletion of any other protein of the FANC pathway causes similar abnormalities in OC physiology and in patients. Furthermore, additional studies are also required to determine if and how the inactivation of the FANC pathway affects the functionality of the OCs, i.e. their intrinsic ability to erode the bone matrix.

Methods

Mice and genotyping

Fanca−/− mice on an FVB background were described previously [69]. The mice were a gift from F. Arwert (Free University Medical Center, Amsterdam, Netherlands) and have been routinely maintained in our laboratory for more than 10 years. Fanca+/– mice were backcrossed with WT FVB/N mice (> 10 generations). As Fanca–/– mice show severely reduced fertility, the WT and Fanca−/− mice used for analysis correspond to siblings derived from crossbreeding of heterozygous mice. Mouse genotyping was performed using Dream-Taq Green DNA Polymerase (Thermo Fisher Scientific, #EP0711). The following primers (Eurogentec) were used: FANCA (forward 5′-GGATCAGGCCTCGAGGCTGG-3′, reverse 5′-TGCAGTAGCTCCTGTAGGCT-3′) and NEO (forward 5′-GACTGGGCACAACAGACAATCGGCT-3′, reverse 5′-TGATATTCGGCAAGCAGGCATCGCC-3′).

Generation of OC cell culture

BM was harvested from mice by flushing tibias and femurs. Red blood cells were eliminated using EasySepTM Red Blood Cell Lysis Buffer (Stem Cell Technologies, #20110). BM cells were then cultured in αMEM with 10% FBS, 100 U/ml penicillin/50 μg/ml streptomycin and 25 ng/ml recombinant murine M-CSF (Peprotech, #315-02). After 48 h, viable progenitors were counted with Trypan Blue and seeded at a concentration of 75,000 cells/cm2 in αMEM with 10% FBS, 100 U/ml penicillin/50 μg/ml streptomycin and 50 ng/ml M-CSF and recombinant murine sRANK ligand (RANKL) (Escherichia coli derived, Peprotech, #315-11). The first OCs started to appear at day 3, and the medium was changed at day 4.

TRAP staining

Mature OC cultures were fixed and stained for TRAP using a commercial kit [Acid Phosphatase, Leukocyte (TRAP) Kit, Sigma, #387A]. Briefly, cells were fixed using a fixative solution composed of 2.5 ml citrate solution, 6.5 ml acetone and 0.8 ml 37% formaldehyde for 30 s at room temperature (RT). Fifty microliters of Fast Garnet GBC Base Solution and fifty microliters of sodium nitrite were mixed for 30 s, left to stand at RT for 2 min and added to 4.5 ml of prewarmed deionized water (37 °C). Then, 50 µl of naphthol AS-BI phosphate solution, 200 µl of acetate solution and 200 µl of tartrate solution were added. The samples were incubated with the complete solution for 20 min at 37 °C. OCs were identified as TRAP-positive cells with 3 or more nuclei and a defined membrane.

Immunofluorescence

Mature OCs were fixed in 4% formaldehyde for 15 min at RT and permeabilized in 0.1% Triton X-100 for 5 min at RT. Then, the cells were incubated with 1× phalloidin-iFluor 488 reagent (1:1000) (Abcam, #ab176753) for 90 min at 37 °C in the dark. For the 53BP1 analysis, the cells were fixed and permeabilized as previously mentioned and then incubated with a primary antibody anti-53BP1 (Abcam, #ab21083) at the same time as phalloidin. After 3 washes with PBS, the cells were incubated with an Alexa Fluor®594 donkey anti-rabbit secondary antibody for 30 min at 37 °C in the dark. Finally, the cells were incubated with a DAPI solution (1:500) for 3 min at RT and observed under a fluorescence microscope.

Western blot

The collected cells were disrupted in lysis buffer (50 mM Tris-HCl pH 7.9, 40 mM NaCl, 1 mM MgCl2, 0.1% SDS, and 1% benzonase [Merck, 70746-3] with protease and phosphatase inhibitors [Roche, 05892791001 and 04906837001]). After incubation for 15 min at RT, protein concentrations were determined using the Bradford assay (Bio-Rad, 500-0006), and the samples were combined with 4× Laemmli buffer containing β-mercaptoethanol and denatured by boiling at 98 °C. The proteins (50 μg) were separated using SDS-PAGE, transferred onto a nitrocellulose membrane (GE Healthcare Life Sciences, Amersham Protran 0.2 μM NC, 10600001), and then exposed to the appropriate antibodies. The proteins were visualized using an enhanced chemiluminescence system (WesternBright ECL by Advansta, K-12045-050) and an ImageQuant LAS 4000 system (GE Healthcare Life Sciences). The following antibodies were used for Western blot analysis: rabbit anti-M-CSFR (Cell Signaling, #3152), mouse anti-RANK (Santa Cruz, #sc-374360), mouse anti-NFATc1 (BioLegend, #649607), mouse anti-Cathepsin K (Santa Cruz, #sc-48353), goat anti-p53 (R&D, #AF1355), rabbit anti-FANCA/FAA (Abcam, #ab272392), rabbit anti-phospho-NF-kB p65 (Ser536) (Cell Signaling, #3033), rabbit anti-RelB (Cell Signaling, #10544), rabbit anti-NF-kB1 p105/p50 (Cell Signaling, #13586), rabbit anti-NF-kB2 p100/p52 (Cell Signaling, #4882), mouse anti-MiTF (Abcam, #ab12039) and goat anti-β-Actin (Abcam, #ab8227). Red Ponceau staining was used as a loading control.

qRT-PCR

Total RNA was isolated using the Maxwell® RSC simplyRNA Cells Kit (Promega, #AS1390) and reverse-transcribed using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, #K1621). qPCR was performed using iTaq™ Universal SYBR® Green Supermix (Bio-Rad, #1725120) and a CFX96 Touch Real-Time PCR Detection System (Bio-Rad). The following primers (Eurogentec) were used:

Rank: forward 5ʹ-GGACAACGGAATCAGATGTGGTC-3ʹ, Tm: 52.0 °C; reverse 5ʹ-CCACAGAGATGAAGAGGAGCAG-3ʹ, Tm: 51.6 °C;

M-Csfr: forward 5ʹ-TGGATGCCTGTGAATGGCTCTG-3ʹ, Tm: 51.6 °C; reverse 5ʹ-GTGGGTGTCATTCCAAACCTGC-3ʹ, Tm: 51.6 °C;

Nfatc1: forward 5ʹ-GGTGCCTTTTGCGAGCAGTATC-3ʹ, Tm: 52.1 °C; reverse 5ʹ-CGTATGGACCAGAATGTGACGG-3ʹ, Tm: 52.3 °C;

Oscar: forward 5ʹ-CGTGCTGACTTCACACCAACAG-3ʹ, Tm: 51.6 °C; reverse 5ʹ-AGTGCAAACCGCCAGGCAGATT-3ʹ, Tm: 51.6 °C;

Dc-Stamp: forward 5ʹ-TTTGCCGCTGTGGACTATCTGC-3ʹ, Tm: 51.7 °C; reverse 5ʹ-GCAGAATCATGGACGACTCCTTG-3ʹ, Tm: 51.9 °C;

Atp6v0d2: forward 5ʹ-ACGGTGATGTCACAGCAGACGT-3ʹ, Tm: 51.6 °C; reverse 5ʹ-CTCTGGATAGAGCCTGCCGCA-3ʹ, Tm: 53.1 °C;

Cathepsin K: forward 5ʹ-AGCAGAACGGAGGCATTGACTC-3ʹ, Tm: 51.7 °C; reverse 5ʹ-CCCTCTGCATTTAGCTGCCTTTG-3ʹ, Tm: 51.7 °C;

Trap: forward 5ʹ-GCGACCATTGTTAGCCACATACG-3ʹ, Tm: 51.6 °C; reverse 5ʹ-CGTTGATGTCGCACAGAGGGAT-3ʹ, Tm: 52.0 °C;

p21 (Cdkn1a): forward 5ʹ-TCGCTGTCTTGCACTCTGGTGT-3ʹ, Tm: 52.0 °C; reverse 5ʹ-CCAATCTGCGCTTGGAGTGATAG-3ʹ, Tm: 51.9 °C.

Transcriptomic analysis

Total RNA was extracted from the WT and Fanca−/− progenitors and OCs as described in the “qRT-PCR” section. Global transcriptomic analysis was performed on total RNA using “Affymetrix Wtplus ClariomS Mouse”. Analysis was performed at the Plateforme de Génomique of the Cochin Institute (Inserm 1016-CNRS 8104), Paris Descartes University, Paris, FR.

Chemicals, peptides, and recombinant proteins

We used recombinant murine TNFα (Peprotech, #315-01A), recombinant human TGF-β1 (HEK293 derived, Peprotech, #100-21), Nutlin-3 (Sigma, #6287), pifithtrin-α (Sigma, #P4359), butyrolactone I (Sigma, #203988) and human/mouse anti-TNF-alpha antibody (R&D Systems, #AF-410-NA) at the indicated concentrations. Antisense oligonucleotides directed against p21 were purchased from Eurogentec (5ʹ-ACA-TCA-CCA-GGA-TTG-GAC-ATG-GGG-GGG-GGG-3ʹ).

Cell lines, culture conditions and siRNA transfection

The murine preosteoblastic cell line MC3T3-E1 Subclone 4 was purchased from ATCC (CRL-2593) and was routinely maintained in αMEM with 10% FBS, 100 U/ml penicillin/50 μg/ml streptomycin, 2 mM l-glutamine and 1 mM sodium pyruvate at 37 °C in a humidified atmosphere containing 5% CO2. For induction of OB differentiation under coculture conditions, the cell line was maintained in the same medium with 50 µg/ml l-ascorbic acid (Sigma #92902) and 4 mM β-glycerophosphate (Merck #G9422).siRNA directed against Fanca was purchased from Dharmacon (#L-058407-01-0005), and cells were transfected using Lipofectamine™ RNAiMAX transfection reagent (Thermo Fisher Scientific, #13779100) following the manufacturer’s instructions.

αMEM was added at the same time as OC precursors 24 h after siRNA transfection.

FACS analysis

TNFα was evaluated by FACS analysis of MC3T3 cells 3 days after siRNA transfection. The cells were fixed for 15 min in 1% PFA/PBS, washed 1× in PBS, incubated for 30 min in the dark at RT at the appropriate dilution (1:100) with a FITC-conjugated anti-mouse TNFα antibody (BioLegend, #MP6-XT22) and washed 1× in PBS. The cells were then analyzed with a BD Accuri™ C6 Cytometer.

Bone microarchitecture and histomorphometry

Cortical bone and trabecular bone microarchitecture assessment was performed on femurs using a high-resolution X-ray microcomputed tomography (micro-CT) system (Quantum FX Caliper, Life Sciences, Perkin Elmer). Micro-CT datasets were analyzed using the built-in multiplanar reconstruction tool Osirix 5.8 (Pixmeo). The reader was blinded to the status of the mouse (WT or Fanca−/−). For the cortical bone analysis of the femur, the following parameters were used: cross-sectional area (TtAr), cortical bone area (CtAr), cortical area fraction (CtAr/TtAr) and cortical thickness (CtTh). For the trabecular bone analysis of the femur, the following parameters were used: bone volume/total volume (BV/TV) ratio, trabecular number (TbN), trabecular separation (TbSp) and trabecular thickness (TbTh). Analyses were performed following published guidelines [71, 72].

Statistical analysis

The results are expressed as the mean value ± SEM. Data were analyzed using Prism (GraphPad software, version 9). Differences were analyzed with unpaired and/or paired two-tailed t tests. Significance was set at 0.05.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its Additional information files. Indeed, data from each single mouse are presented as ‘dots’ in each figure. However, the datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Mehdipour P, Santoro F, Minucci S. Epigenetic alterations in acute myeloid leukemias. FEBS J. 2015;282:1786–800.

    Article  CAS  PubMed  Google Scholar 

  2. Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med. 2016;22:792–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Saha S, Murmu KC, Biswas M, Chakraborty S, Basu J, Madhulika S, et al. Transcriptomic analysis identifies RNA binding proteins as putative regulators of myelopoiesis and leukemia. Front Oncol. 2019;9:692.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Adamia S, Haibe-Kains B, Pilarski PM, Bar-Natan M, Pevzner S, Avet-Loiseau H, et al. A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res. 2014;20:1135–45.

    Article  CAS  PubMed  Google Scholar 

  5. Zhou J, Chng W-J. Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia. Stem Cell Investig. 2017;4:6.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kreitz J, Schönfeld C, Seibert M, Stolp V, Alshamleh I, Oellerich T, et al. Metabolic plasticity of acute myeloid leukemia. Cells. 2019;8:E805.

    Article  Google Scholar 

  7. Rashkovan M, Ferrando A. Metabolic dependencies and vulnerabilities in leukemia. Genes Dev. 2019;33:1460–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133:1039–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther. 2020;5:288.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Nilles N, Fahrenkrog B. Taking a bad turn: compromised DNA damage response in leukemia. Cells. 2017;6:E11.

    Article  Google Scholar 

  11. Biechonski S, Yassin M, Milyavsky M. DNA-damage response in hematopoietic stem cells: an evolutionary trade-off between blood regeneration and leukemia suppression. Carcinogenesis. 2017;38:367–77.

    Article  CAS  PubMed  Google Scholar 

  12. Delia D, Mizutani S. The DNA damage response pathway in normal hematopoiesis and malignancies. Int J Hematol. 2017;106:328–34.

    Article  CAS  PubMed  Google Scholar 

  13. Ruggero D, Shimamura A. Marrow failure: a window into ribosome biology. Blood. 2014;124:2784–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Galili N, Qasim SA, Raza A. Defective ribosome biogenesis in myelodysplastic syndromes. Haematologica. 2009;94:1336–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Alter BP, Giri N, Savage SA, Rosenberg PS. Telomere length in inherited bone marrow failure syndromes. Haematologica. 2015;100:49–54.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lansdorp PM. Maintenance of telomere length in AML. Blood Adv. 2017;1:2467–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505:327–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Birbrair A, Frenette PS. Niche heterogeneity in the bone marrow. Ann N Y Acad Sci. 2016;1370:82–96.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Balderman SR, Calvi LM. Biology of BM failure syndromes: role of microenvironment and niches. Hematology Am Soc Hematol Educ Progr. 2014;2014:71–6.

    Article  Google Scholar 

  20. Duarte D, Hawkins ED, Lo Celso C. The interplay of leukemia cells and the bone marrow microenvironment. Blood. 2018;131:1507–11.

    Article  CAS  PubMed  Google Scholar 

  21. Houshmand M, Blanco TM, Circosta P, Yazdi N, Kazemi A, Saglio G, et al. Bone marrow microenvironment: the guardian of leukemia stem cells. World J Stem Cells. 2019;11:476–90.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Mansour A, Abou-Ezzi G, Sitnicka E, Jacobsen SEW, Wakkach A, Blin-Wakkach C. Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. J Exp Med. 2012;209:537–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Galán-Díez M, Kousteni S. The osteoblastic niche in hematopoiesis and hematological myeloid malignancies. Curr Mol Biol Rep. 2017;3:53–62.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Miyamoto T. Role of osteoclasts in regulating hematopoietic stem and progenitor cells. World J Orthop. 2013;4:198–206.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Curto-Garcia N, Harrison C, McLornan DP. Bone marrow niche dysregulation in myeloproliferative neoplasms. Haematologica. 2020;105:1189–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Dong L, Yu W-M, Zheng H, Loh ML, Bunting ST, Pauly M, et al. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. Nature. 2016;539:304–8.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Leung R, Cuddy K, Wang Y, Rommens J, Glogauer M. Sbds is required for Rac2-mediated monocyte migration and signaling downstream of RANK during osteoclastogenesis. Blood. 2011;117:2044–53.

    Article  CAS  PubMed  Google Scholar 

  28. Lymperi S, Ersek A, Ferraro F, Dazzi F, Horwood NJ. Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood. 2011;117:1540–9.

    Article  CAS  PubMed  Google Scholar 

  29. Bowers M, Zhang B, Ho Y, Agarwal P, Chen C-C, Bhatia R. Osteoblast ablation reduces normal long-term hematopoietic stem cell self-renewal but accelerates leukemia development. Blood. 2015;125:2678–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yokota A, Kimura S, Tanaka R, Takeuchi M, Yao H, Sakai K, et al. Osteoclasts are involved in the maintenance of dormant leukemic cells. Leuk Res. 2010;34:793–9.

    Article  CAS  PubMed  Google Scholar 

  31. Nalepa G, Clapp DW. Fanconi anaemia and cancer: an intricate relationship. Nat Rev Cancer. 2018;18:168–85.

    Article  CAS  PubMed  Google Scholar 

  32. Gueiderikh A, Rosselli F, Neto JBC. A never-ending story: the steadily growing family of the FA and FA-like genes. Genet Mol Biol. 2017;40:398–407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Renaudin X, Rosselli F. The FANC/BRCA pathway releases replication blockades by eliminating DNA interstrand cross-links. Genes (Basel). 2020;11:585.

    Article  CAS  PubMed  Google Scholar 

  34. Pichierri P, Rosselli F. Fanconi anemia proteins and the s phase checkpoint. Cell Cycle. 2004;3:698–700.

    Article  CAS  PubMed  Google Scholar 

  35. Helbling-Leclerc A, Dessarps-Freichey F, Evrard C, Rosselli F. Fanconi anemia proteins counteract the implementation of the oncogene-induced senescence program. Sci Rep. 2019;9:17024.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Helbling-Leclerc A, Garcin C, Rosselli F. Beyond DNA repair and chromosome instability-Fanconi anaemia as a cellular senescence-associated syndrome. Cell Death Differ. 2021;28:1159–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Gueiderikh A, Maczkowiak-Chartois F, Rouvet G, Souquère-Besse S, Apcher S, Diaz J-J, et al. Fanconi anemia A protein participates in nucleolar homeostasis maintenance and ribosome biogenesis. Sci Adv. 2021;7:eabb5414.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Gueiderikh A, Maczkowiak-Chartois F, Rosselli F. A new frontier in Fanconi anemia: from DNA repair to ribosome biogenesis. Blood Rev. 2022;52:100904.

    Article  CAS  PubMed  Google Scholar 

  39. Sondalle SB, Longerich S, Ogawa LM, Sung P, Baserga SJ. Fanconi anemia protein FANCI functions in ribosome biogenesis. Proc Natl Acad Sci USA. 2019;116:2561–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Ibañez-Cabellos JS, Seco-Cervera M, Perez-Machado G, Garcia-Gimenez JL, Pallardo FV. Characterization of the antioxidant systems in different complementation groups of Dyskeratosis Congenita. Free Radic Biol Med. 2014;75(Suppl 1):S34.

    Article  PubMed  Google Scholar 

  41. Briot D, Macé-Aimé G, Subra F, Rosselli F. Aberrant activation of stress-response pathways leads to TNF-alpha oversecretion in Fanconi anemia. Blood. 2008;111:1913–23.

    Article  CAS  PubMed  Google Scholar 

  42. Zanier R, Briot D, Dugas du Villard J-A, Sarasin A, Rosselli F. Fanconi anemia C gene product regulates expression of genes involved in differentiation and inflammation. Oncogene. 2004;23:5004–13.

    Article  CAS  PubMed  Google Scholar 

  43. Rosselli F, Sanceau J, Gluckman E, Wietzerbin J, Moustacchi E. Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor alpha. Blood. 1994;83:1216–25.

    Article  CAS  PubMed  Google Scholar 

  44. Zhang H, Kozono DE, O’Connor KW, Vidal-Cardenas S, Rousseau A, Hamilton A, et al. TGF-β inhibition rescues hematopoietic stem cell defects and bone marrow failure in fanconi anemia. Cell Stem Cell. 2016;18:668–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ceccaldi R, Parmar K, Mouly E, Delord M, Kim JM, Regairaz M, et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell. 2012;11:36–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Rosselli F, Ridet A, Soussi T, Duchaud E, Alapetite C, Moustacchi E. p53-dependent pathway of radio-induced apoptosis is altered in Fanconi anemia. Oncogene. 1995;10:9–17.

    CAS  PubMed  Google Scholar 

  47. Rodríguez A, Zhang K, Färkkilä A, Filiatrault J, Yang C, Velázquez M, et al. MYC promotes bone marrow stem cell dysfunction in fanconi anemia. Cell Stem Cell. 2021;28:33-47.e8.

    Article  PubMed  Google Scholar 

  48. Oppezzo A, Bourseguin J, Renaud E, Pawlikowska P, Rosselli F. Microphthalmia transcription factor expression contributes to bone marrow failure in Fanconi anemia. J Clin Invest. 2020;130:1377–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Zhou Y, He Y, Xing W, Zhang P, Shi H, Chen S, et al. An abnormal bone marrow microenvironment contributes to hematopoietic dysfunction in Fanconi anemia. Haematologica. 2017;102:1017–27.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Xu J, Li X, Cole A, Sherman Z, Du W. Reduced cell division control protein 42 activity compromises hematopoiesis-supportive function of fanconi anemia mesenchymal stromal cells. Stem Cells. 2018;36:785–95.

    Article  CAS  PubMed  Google Scholar 

  51. Amarachintha S, Sertorio M, Wilson A, Li X, Pang Q. Fanconi anemia mesenchymal stromal cells-derived glycerophospholipids skew hematopoietic stem cell differentiation through toll-like receptor signaling. Stem Cells. 2015;33:3382–96.

    Article  CAS  PubMed  Google Scholar 

  52. Mantelli M, Avanzini MA, Rosti V, Ingo DM, Conforti A, Novara F, et al. Comprehensive characterization of mesenchymal stromal cells from patients with Fanconi anaemia. Br J Haematol. 2015;170:826–36.

    Article  CAS  PubMed  Google Scholar 

  53. Kim JH, Kim N. Regulation of NFATc1 in osteoclast differentiation. J Bone Metab. 2014;21:233–41.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Strub T, Giuliano S, Ye T, Bonet C, Keime C, Kobi D, et al. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene. 2011;30:2319–32.

    Article  CAS  PubMed  Google Scholar 

  55. Bourseguin J, Bonet C, Renaud E, Pandiani C, Boncompagni M, Giuliano S, et al. FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells. Sci Rep. 2016;6:36539.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Zauli G, Rimondi E, Corallini F, Fadda R, Capitani S, Secchiero P. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway. J Bone Miner Res. 2007;22:1621–30.

    Article  CAS  PubMed  Google Scholar 

  57. Zhang Y, Liao J-M, Zeng SX, Lu H. p53 downregulates Down syndrome-associated DYRK1A through miR-1246. EMBO Rep. 2011;12:811–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Luo G, Li F, Li X, Wang Z-G, Zhang B. TNF-α and RANKL promote osteoclastogenesis by upregulating RANK via the NF-κB pathway. Mol Med Rep. 2018;17:6605–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Fuller K, Lean JM, Bayley KE, Wani MR, Chambers TJ. A role for TGFbeta(1) in osteoclast differentiation and survival. J Cell Sci. 2000;113(Pt 13):2445–53.

    Article  CAS  PubMed  Google Scholar 

  60. Boyce BF, Xiu Y, Li J, Xing L, Yao Z. NF-κB-mediated regulation of osteoclastogenesis. Endocrinol Metab (Seoul). 2015;30:35–44.

    Article  CAS  PubMed  Google Scholar 

  61. Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res. 1992;7:683–92.

    Article  CAS  PubMed  Google Scholar 

  62. Marion W, Boettcher S, Ruiz-Torres S, Lummertz da Rocha E, Lundin V, Morris V, et al. An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor cell differentiation. Blood Adv. 2020;4:4679–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Walter D, Lier A, Geiselhart A, Thalheimer FB, Huntscha S, Sobotta MC, et al. Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. Nature. 2015;520:549–52.

    Article  PubMed  Google Scholar 

  64. Flach J, Bakker ST, Mohrin M, Conroy PC, Pietras EM, Reynaud D, et al. Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. Nature. 2014;512:198–202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Rossi DJ, Bryder D, Seita J, Nussenzweig A, Hoeijmakers J, Weissman IL. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature. 2007;447:725–9.

    Article  CAS  PubMed  Google Scholar 

  66. Mazon M, Julien J, Ung R-V, Picard S, Hamoudi D, Tam R, et al. Deletion of the Fanconi anemia C gene in mice leads to skeletal anomalies and defective bone mineralization and microarchitecture. J Bone Miner Res. 2018;33:2007–20.

    Article  CAS  PubMed  Google Scholar 

  67. Li Y, Chen S, Yuan J, Yang Y, Li J, Ma J, et al. Mesenchymal stem/progenitor cells promote the reconstitution of exogenous hematopoietic stem cells in Fancg−/− mice in vivo. Blood. 2009;113:2342–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Zhang Q-S, Marquez-Loza L, Eaton L, Duncan AW, Goldman DC, Anur P, et al. Fancd2−/− mice have hematopoietic defects that can be partially corrected by resveratrol. Blood. 2010;116:5140–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Cheng NC, van de Vrugt HJ, van der Valk MA, Oostra AB, Krimpenfort P, de Vries Y, et al. Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet. 2000;9:1805–11.

    Article  CAS  PubMed  Google Scholar 

  70. Pawlikowska P, Fouchet P, Vainchenker W, Rosselli F, Naim V. Defective endomitosis during megakaryopoiesis leads to thrombocytopenia in Fanca−/− mice. Blood. 2014;124:3613–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25:1468–86.

    Article  PubMed  Google Scholar 

  72. Whittier DE, Boyd SK, Burghardt AJ, Paccou J, Ghasem-Zadeh A, Chapurlat R, et al. Guidelines for the assessment of bone density and microarchitecture in vivo using high-resolution peripheral quantitative computed tomography. Osteoporos Int. 2020;31:1607–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank individuals from the UMR9019-CNRS for helpful discussion and Tudor Manoliu from the Imaging and Cytometry Platform of Gustave Roussy Cancer Center.

Funding

Research in the FR lab is funded by La Ligue Contre le Cancer. AO was supported by a doctoral fellowship from the “Ministére de l’Enseignement supérieur, de la Recherche et de l’Innovation” and the “Fondation pour La Recherche Médicale” (FDT202001010821).

Author information

Author notes

  1. Alessia Oppezzo

    Present address: IFOM ETS, The AIRC Institute of Molecular Oncology, Milan, Italy

Authors and Affiliations

  1. CNRS UMR9019, Équipe labellisée La Ligue contre le Cancer, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France

    Alessia Oppezzo, Lovely Monney, Frédérique Maczkowiak-Chartois & Filippo Rosselli

  2. Gustave Roussy Cancer Center, Villejuif, France

    Alessia Oppezzo, Lovely Monney, Frédérique Maczkowiak-Chartois & Filippo Rosselli

  3. Université Paris Saclay, Orsay, France

    Alessia Oppezzo, Lovely Monney, Frédérique Maczkowiak-Chartois & Filippo Rosselli

  4. URP2496 Pathologies, Imagerie et Biothérapies Orofaciales et Plateforme Imagerie du Vivant (PIV), FHU-DDS-net, Dental School, Université de Paris, Montrouge, France

    Henri Kilian & Lofti Slimani

Authors
  1. Alessia Oppezzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lovely Monney
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henri Kilian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lofti Slimani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frédérique Maczkowiak-Chartois
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Filippo Rosselli
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AO performed experiments, analyzed the data, and wrote the paper. LM and FM performed the experiments. HK and LS performed bone morphology analysis. FR designed the study, supervised the study, wrote the paper and acquired funding.

Corresponding author

Correspondence to Filippo Rosselli.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Study approval

This project was officially approved by the Animal Experimentation Ethics Committee (no. 26) of Gustave Roussy and conducted in accordance with French laws and regulations.

Competing interests

The authors have no relevant financial or nonfinancial interests to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1

: Figure S1. A. Number of OCs for field, number of nuclei for OCand surface of the OCsat days 3, 4 and 5 of differentiation in 1-year-old mice. B. Relative Fanca expression evaluated by qRT-PCR in progenitors and OCs at day 4 of differentiation from WT and Fanca−/− mice. Data are shown as the mean ± SEM. C. Western blot showing Fanca in OCs from WT and Fanca−/− mice at days 4 and 5 of differentiation. b-Actin was used as a loading control. Figure S2. A. From left to right: relative Rank, M-Csfr, Nfatc1, Dc-Stamp and Cathepsin K expression evaluated by qRT-PCR in progenitors and OCs at day 4 of differentiation from 1-year-old WT and Fanca−/− mice. Data are shown as the mean ± SEM. B. Western blot showing Nfatc1 in OCs from 1-year-old WT and Fanca−/− mice at day 4 of differentiation. b-Actin was used as a loading control. Right: Relative protein expression of Nfatc1 in OCs from 1-year-old WT and Fanca−/− mice at day 4 of differentiation. C. Western blotand quantificationshowing Mitf expression in OCs from WT and Fanca−/− mice at day 4 of differentiation. Figure S3. A. Number of OCs for field, number of nuclei for Csand surface of the OCsat day 4 of differentiation in the WT and Fanca−/− cells left untreated or treated with TGFb. Figure S4. A. Representative µCT images of the distal femur and femur sections in WT and Fanca−/− mice. B. Comparison of trabecular status in bone from WT and Fanca−/− mice. Figure S5. A. Number of OCs per field from WT and Fanca−/− cells cultured in the absence or presence of TNFα on day 4 of differentiation. B. Number of OCs per field from the WT and Fanca−/− cells plated on WT or Fanca-depleted MC3T3 cells and treated or not with an inhibitory anti- TNFα antibody at day 4 of differentiation. C. Number of OCs per field from the WT cells plated on WT or Fanca-depleted MC3T3 cells and treated or not with an inhibitory anti- TNFα antibody at day 4 of differentiation. Figure S6. Uncropped gel images used for representative Western blot.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oppezzo, A., Monney, L., Kilian, H. et al. Fanca deficiency is associated with alterations in osteoclastogenesis that are rescued by TNFα. Cell Biosci 13, 115 (2023). https://doi.org/10.1186/s13578-023-01067-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13578-023-01067-7

Keywords

Cell & Bioscience

ISSN: 2045-3701

Contact us